Weight loss drugs work through three main strategies: reducing appetite by acting on the brain, slowing digestion so you feel full longer, or blocking your body from absorbing dietary fat. The newest and most effective class, GLP-1 receptor agonists, does the first two simultaneously. Here’s how each type works inside your body and what that means in practice.
GLP-1 Drugs: The Biggest Shift in Weight Loss Treatment
Semaglutide (Wegovy) and tirzepatide (Zepbound) belong to a class of drugs that mimic a hormone your gut naturally produces after eating, called GLP-1. Your body uses this hormone to signal fullness. These drugs deliver a much stronger, longer-lasting version of that signal, and they target two systems at once: your brain and your digestive tract.
In the brain, GLP-1 receptors sit in several areas of the hypothalamus, the region that regulates hunger and energy balance. When the drug activates those receptors, it suppresses the neurons responsible for driving appetite and stimulates the ones that promote satiety. The net effect is that your brain gets a persistent “you’ve eaten enough” message, even when your stomach isn’t particularly full. Animal studies show that when researchers block GLP-1 receptors in specific hypothalamic areas, the animals gain weight and eat more, confirming how central this signaling pathway is to appetite control.
At the same time, these drugs slow gastric emptying, the rate at which food leaves your stomach and enters your small intestine. They do this by acting on the vagus nerve, which controls the muscular contractions that move food through your digestive tract. The result is that a meal physically stays in your stomach longer, so you feel satisfied sooner and stay full for hours after eating. Many people on these medications describe simply not thinking about food between meals.
Tirzepatide goes a step further. It mimics two gut hormones (GLP-1 and GIP) rather than one, which is why clinical trials have shown it produces greater weight loss than semaglutide alone.
How Fat Blockers Work Differently
Orlistat (sold as Xenical by prescription and Alli over the counter) takes a completely different approach. Instead of changing your appetite, it prevents your body from absorbing about 30% of the fat you eat. It does this by disabling lipase, the enzyme your pancreas and stomach produce to break dietary fat into molecules small enough to absorb. With lipase partially shut down, undigested fat passes straight through your digestive system.
This mechanism is effective but comes with obvious tradeoffs. The unabsorbed fat has to go somewhere, and that means oily stools, gas, and urgent bowel movements, particularly after high-fat meals. These side effects are essentially the drug working as intended, and they tend to push people toward lower-fat diets. The weight loss with orlistat is more modest than with GLP-1 drugs, but it remains an option for people who prefer a non-hormonal approach.
Appetite Suppressants That Target Brain Chemistry
Phentermine-topiramate (Qsymia) combines two older drugs that reduce appetite through different brain pathways. Phentermine triggers the release of norepinephrine, a stress-related chemical messenger, in the hypothalamus. This raises levels of leptin, a hormone that signals your body has enough energy stored, which suppresses hunger. It’s essentially the same “fight or flight” chemistry that kills your appetite when you’re anxious or stressed, just delivered in a controlled dose.
Topiramate was originally developed as an anti-seizure medication, and researchers noticed patients on it lost weight. It boosts the activity of GABA, a calming brain chemical, while dampening certain excitatory signals. The exact mechanism behind its weight loss effect still isn’t fully understood, but the combination with phentermine produces meaningful appetite reduction.
Another combination drug, naltrexone-bupropion (Contrave), pairs an opioid-blocking compound with an antidepressant. Bupropion activates appetite-suppressing neurons in the hypothalamus, while naltrexone prevents those same neurons from shutting themselves off through a natural feedback loop. Together, they sustain appetite suppression longer than either drug alone.
Why GI Side Effects Are So Common
The most frequently reported side effects of GLP-1 drugs are nausea, vomiting, diarrhea, and constipation. These aren’t random reactions. They’re a direct consequence of how the drugs work. By reducing intestinal motility, GLP-1 drugs can slow digestion to the point where it resembles gastroparesis, a condition in which the stomach takes far too long to empty. This is why nausea tends to be worst when starting treatment or increasing the dose: your gut is adjusting to a dramatically slower pace of digestion.
For most people, these side effects fade over several weeks as the body adapts. Doctors typically start patients on a low dose and increase it gradually for this reason. In rare cases, the slowed motility raises concerns about intestinal blockage, and people scheduled for surgery may be asked to stop the medication beforehand to reduce aspiration risk during anesthesia.
The Muscle Loss Problem
One underappreciated consequence of these drugs is that you don’t just lose fat. Lean body mass, which includes muscle, can account for 15% to 40% of the total weight lost on GLP-1 therapies. That’s a significant range, and it matters because muscle loss can reduce your metabolic rate, weaken your body, and make it harder to maintain weight loss over time.
This is why many doctors now recommend resistance training and adequate protein intake alongside these medications. The drug reduces your appetite, which makes it easy to undereat protein without realizing it. Deliberately prioritizing protein-rich foods and strength exercises can shift the ratio of weight loss more toward fat and away from muscle.
What Happens When You Stop
These drugs do not cure obesity. They manage it, much like blood pressure medication manages hypertension. A systematic review published in The Lancet found that one year after stopping GLP-1 drugs, people regained 60% of the weight they had lost during treatment. Beyond that point, the trend continued, with regain estimated to plateau at roughly 75% of the original weight lost.
This happens because the drugs suppress appetite and slow digestion only while you’re taking them. Once the medication clears your system, your baseline hunger signals return, and so does your previous rate of gastric emptying. Your hypothalamus resumes its pre-treatment activity patterns. For many people, this means the biological drive to eat returns to levels that originally caused the weight gain.
This doesn’t mean the drugs are pointless. The cardiovascular and metabolic benefits of even temporary weight loss are real. But it does mean that most people who respond well to these medications will need to continue them long term to maintain results, which is why all six FDA-approved obesity drugs (orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide, and tirzepatide) are approved for long-term use rather than short courses.
How These Drugs Compare in Practice
- GLP-1 and dual-hormone drugs (semaglutide, tirzepatide, liraglutide) produce the largest weight loss, typically 15% to 25% of body weight with tirzepatide and 12% to 17% with semaglutide. They’re injected weekly or daily depending on the specific drug.
- Phentermine-topiramate is taken as a daily pill and generally produces moderate weight loss, in the range of 8% to 10% of body weight.
- Naltrexone-bupropion is also a daily pill with somewhat more modest results, typically around 5% to 8% of body weight.
- Orlistat produces the least dramatic results, usually 5% to 7% of body weight, but works through a completely non-hormonal mechanism and is available over the counter at a lower dose.
Four of these medications are also approved for adolescents aged 12 and older. A separate drug, setmelanotide, is approved for children ages 6 and up but only for those with specific rare genetic disorders confirmed by testing. It works on a different brain pathway entirely, targeting receptors involved in energy balance that are dysfunctional in these particular genetic conditions.